Creative Medical Technology Holdings, Inc. Common Stock (CELZ) — Analysis Summary
Creative Medical Technology Holdings, Inc. Common Stock (CELZ) has a market cap of $6.39M with year-over-year revenue growth of -45.5%. Net margin stands at -99916.8%. The stock trades at a P/E ratio of -1.1.
Key Takeaways
- Revenue changed -45.5% year-over-year
- Net margin of -99916.8%
- P/E ratio of -1.1
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CELZ posted revenue growth of -45.5% and trades at a P/E of -1.1.
Creative Medical Technology Holdings, Inc. Common Stock (CELZ)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -208004.4% — severe operating losses
Net margin at -201355.4% — losses exceed revenue (possible one-time charges)
Revenue fell 50.0% vs the prior period.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
4
Headquarters
PHOENIX, AZ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.